Dr. Jean-Claude Tardif Receives the Prestigious Margolese National Heart Disorders Prize

September 10, 2021

The Montreal Heart Institute (MHI) is proud to announce that Dr. Jean-Claude Tardif has been honoured with the 2021 Margolese National Heart Disorders Prize.

This prestigious distinction is awarded annually to a Canadian physician or scientist who makes outstanding contributions to heart disorders’ treatment, amelioration, or cure.

A leading researcher at the Institute
Dr. Tardif is one of the most gifted cardiology researchers of his time. Director of the MHI Research Centre and Professor of Medicine at the Université de Montréal (UdeM), he has received numerous national and international distinctions for his work, including the Order of Canada, the country’s highest honour.

His research focuses on the pathophysiology and treatment of atherosclerosis using precision medicine, pharmacogenomics, advanced molecular approaches, innovative imaging, and randomized clinical trials to tackle relevant and vital questions.

As an international leader in implementing and executing clinical studies, Dr. Tardif has created huge patient cohorts to advance research in genomics and precision medicine.

His work, including more than 700 scientific papers, has been widely cited worldwide. Some of his clinical trials have informed cardiology guidelines and led to the regulatory acceptance of drugs for clinical practice, including the recent approval of low-dose colchicine for treating cardiovascular diseases by Health Canada.

He has also developed exceptional research infrastructures in Montreal throughout his career, including the Beaulieu-Saucier Pharmacogenomics Centre at the MHI and the Centre of Excellence in Personalized Medicine (CEPMED).

Margolese National Heart Disorders Prize
This distinction was created in 2011 by an estate gift made to the University of British Columbia by Leonard Herbert Margolese. The prize is awarded with the expectation that the recipient will continue to make outstanding contributions to cardiology. Among the criteria considered are impact on policy and practice, forging partnerships with scientists and others to foster heart disorders research, implement discoveries, and cultivate future leaders in the field.